Study details
Enrolling now
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
NCT IDNCT05413850ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
82
Study length
about 5.7 years
Ages
18+
Sex
Male only
Locations
5 sites in FL, GA, NE +1
About this study
Researchers are testing a new treatment, Lutetium (177Lu) rhPSMA-10.1 injection, to see if it can help fight prostate cancer that has spread and become resistant to other treatments. The trial will involve men with advanced prostate cancer who have not responded well to hormone therapy. This is an interventional trial where participants receive the new treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive 18F-rhPSMA-7.3 injection (in phase 1 only)
- 2.Receive Lutetium (177Lu) rhPSMA-10.1 Injection
PhasePhase 1/Phase 2
Routeinjection
Primary goalPhase 1 Frequency and nature of TEAEs
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
injection
Endpoints
Primary: Phase 1 Frequency and nature of TEAEs
Body systems
Oncology